Here is Matt Lowdon‘s weekly deal update for Medtech and Biotech. The top headlines include news from companies involved with TPD, vascular, asthma care, cell programming and more.
🔔 Startup Spiro Medical snares $67M in series A funding for asthma treatment
🔔Surgerii Robotics raises $100M to fund global expansion
🔔 GSK has committed $50 million in upfront capital and near-term milestones to secure a license to two cancer research foundation models from NOETIK.
🔔 EpiBiologics raises $107M for its protein-degrading cancer drug
🔔 Madrigal Pharmaceuticals has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its approved liver disease med Rezdiffra.
🔔 Galway medtech Vivasure Medical Ltd. acquired in deal worth up to €185m. Boston-headquartered medical device group Haemonetics agrees to pay €100m upfront for Enterprise Ireland-backed company
🔔 Paris-based start-up Enodia Therapeutics has secured €20.7 million in seed funding to advance its early-stage pipeline of targeted protein degradation
🔔 AirNexis Therapeutics is taking flight with $200 million and a clinical-stage asset from a Chinese pharma that aims to treat lung disease.
🔔 Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing.
🔔 1st biotech IPO of 2026 sees Aktis Oncology bring in $318M via upsized offering.
🔔 Equipped with $160M series A, Alveus Therapeutics Inc debuts into crowded obesity development landscape
🔔 Ventyx Biosciences has achieved its goal of securing Big Pharma commitment to its pipeline, with Eli Lilly and Company swooping in to buy the inflammation biotech outright for $1.2 billion.
🔔 Amgen has agreed to acquire Dark Blue Therapeutics in a deal valued at up to $840 million, as the biopharmaceutical company continues to build out its early-stage oncology pipeline.
🔔 STRM.BIO, a biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced $8 million in Series Seed 2 financing
🔔 Basilea Pharmaceutica strikes up to $48.5m antifungal deal with U.S. biotech Prokaryotics, Inc.
🔔 4 years after its initial series A round, Engitix Therapeutics has completed a $25 million series A extension, led by Netherton Investments
🔔 bit.bio, Cambridge-based pioneer in next-generation human cell programming, has successfully closed a $50 million Series C funding round led by M&G Investments
===============
Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.